Cargando…

Fatal adverse events with molecular targeted agents in the treatment of advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials

AIMS: Concerns have increased about the risk of fatal adverse events (FAEs) associated with molecular targeted agents (MTAs) in the treatment of advanced hepatocellular carcinoma (HCC). The purpose of this study is to investigate the overall incidence and risk of FAEs in advanced HCC with administra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xiaofei, Wan, Jia, Wu, Zhenping, Tu, Juncai, Hu, Yongtao, Wu, Shuang, Lou, Lianqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151100/ https://www.ncbi.nlm.nih.gov/pubmed/30271119 http://dx.doi.org/10.2147/DDDT.S151241

Ejemplares similares

Metabolic syndrome and the incidence of hepatocellular carcinoma: a meta-analysis of cohort studies
por: Chen, Yongxin, et al.
Publicado: (2018)

Statin and the risk of hepatocellular carcinoma in patients with hepatitis B virus or hepatitis C virus infection: a meta-analysis
por: Li, Xiaofei, et al.
Publicado: (2020)

Treatment-related severe and fatal adverse events with molecular targeted agents in the treatment of advanced gastric cancer: a meta-analysis
por: Wang, Liang, et al.
Publicado: (2017)

Efficacy of anti-VEGF agents in the treatment of elderly hepatocellular carcinoma: a systematic review
por: Li, Xiaofei, et al.
Publicado: (2017)

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: Nivolumab-related serious/fatal adverse events
por: Zhao, Bin, et al.
Publicado: (2018)

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
por: Zhao, Bin, et al.
Publicado: (2019)

Efficacy and Safety of Adjunctive Recombinant Human Interleukin-2 for Patients with Pulmonary Tuberculosis: A Meta-Analysis
por: Sheng, Lina, et al.
Publicado: (2022)

Tolerance and adverse event profile with sorafenib in Indian patients with advanced hepatocellular carcinoma
por: Ostwal, Vikas, et al.
Publicado: (2017)

Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma
por: Schwartz, Gabriel, et al.
Publicado: (2020)

Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis
por: Holmøy, Trygve, et al.
Publicado: (2019)

Blockade of CCN4 attenuates CCl(4)-induced liver fibrosis
por: Li, Xiaofei, et al.
Publicado: (2015)

Acute glycemic variability and risk of mortality in patients with sepsis: a meta-analysis
por: Li, Xiaofei, et al.
Publicado: (2022)

Delayed adverse events in phase I trials of molecularly targeted and cytotoxic agents
por: Jordan, Emma J., et al.
Publicado: (2018)

Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

Fatal acquired coagulation factor V deficiency after hepatectomy for advanced hepatocellular carcinoma as a possible immune checkpoint inhibitor-related adverse event: a case report
por: Arakaki, Shintaro, et al.
Publicado: (2023)

Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma
por: Gu, Xiaoying, et al.
Publicado: (2022)

Hemophagocytic lymphohistiocytosis and disseminated intravascular coagulation are underestimated, but fatal adverse events in chimeric antigen receptor T-cell therapy
por: Song, Zhiqiang, et al.
Publicado: (2023)

Fatal Events Associated with Adverse Drug Reactions in the Korean National Pharmacovigilance Database
por: Jo, Hyeong-Geun, et al.
Publicado: (2021)

Comment on “Are inflammatory and malnutrition markers associated with metabolic syndrome in patients with sarcoidosis?”
por: Tu, Juncai, et al.
Publicado: (2022)

Proton pump inhibitor use and mortality in patients with cirrhosis: a meta-analysis of cohort studies
por: Wu, Xiaoli, et al.
Publicado: (2020)

An Updated Meta-Analysis of Fatal Adverse Events Caused by Bevacizumab Therapy in Cancer Patients
por: Huang, Hongxin, et al.
Publicado: (2014)

Adverse events risk associated with anti-VEGFR agents in the treatment of advanced nonsmall-cell lung cancer: A meta-analysis
por: Gu, Biao, et al.
Publicado: (2016)

Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-Analysis
por: Wang, Xuewen, et al.
Publicado: (2020)

Sorafenib-Related Adverse Events in Predicting the Early Radiologic Responses of Hepatocellular Carcinoma
por: Lee, Shou-Wu, et al.
Publicado: (2019)

Fatal thyrocardiac event
por: Khutia, Samit Kumar, et al.
Publicado: (2010)

Statin use and the prognosis of patients with hepatocellular carcinoma: a meta-analysis
por: Li, Xiaofei, et al.
Publicado: (2020)

Fatal adverse events of rivaroxaban combined with aspirin: an analysis using data from VigiBase
por: Zhang, Qingxia, et al.
Publicado: (2022)

Exploring Adverse Events and Utilization of Topical Hemostatic Agents in Surgery
por: O’Hanlan, Katherine A., et al.
Publicado: (2022)

Nintedanib in advanced NSCLC: management of adverse events
por: Lemmens, Liesbeth
Publicado: (2016)

Opportunities for Web-based Drug Repositioning: Searching for Potential Antihypertensive Agents with Hypotension Adverse Events
por: Wang, Kejian, et al.
Publicado: (2016)

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
por: Xiong, Rui, et al.
Publicado: (2023)

Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
por: Zhou, Jianxing, et al.
Publicado: (2022)

Advancing drug safety science by integrating molecular knowledge with post‐marketing adverse event reports
por: Soldatos, Theodoros G., et al.
Publicado: (2022)

Advance of promising targets and agents against COVID-19 in China
por: Duan, Yongtao, et al.
Publicado: (2020)

Letter Regarding “Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma”
por: Wang, Yinhan, et al.
Publicado: (2022)

Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma
por: Soria, Anna, et al.
Publicado: (2022)

Recent Advances in the Management of Adverse Events Associated with Lorlatinib
por: Liao, Dehua, et al.
Publicado: (2023)

Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis
por: Jiang, Yi, et al.
Publicado: (2019)

The treatment-related mortality score is associated with non-fatal adverse events following intensive AML induction chemotherapy
por: Buckley, S A, et al.
Publicado: (2015)

Fatal Adverse Events of Dabigatran Combined With Aspirin in Elderly Patients: An Analysis Using Data From VigiBase
por: Zhang, Qingxia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6goe8kdijbg977jhjiquicblla